Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

238 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
HDL and triglyceride as therapeutic targets.
Fruchart JC, Duriez P. Fruchart JC, et al. Among authors: duriez p. Curr Opin Lipidol. 2002 Dec;13(6):605-16. doi: 10.1097/00041433-200212000-00003. Curr Opin Lipidol. 2002. PMID: 12441884 Review.
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Després JP, Duriez P, Eckel RH, Ezhov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koenig W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Nuñez-Cortes JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Ponte-Negretti CI, Pradhan A, Ray KK, Reiner Ž, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sritara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskinen MR, Tenenbaum A, Tokgözoğlu LS, Tomlinson B, Tybjærg-Hansen A, Valensi P, Vrablík M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A, Libby P. Fruchart JC, et al. Among authors: duriez p. Cardiovasc Diabetol. 2019 Jun 4;18(1):71. doi: 10.1186/s12933-019-0864-7. Cardiovasc Diabetol. 2019. PMID: 31164165 Free PMC article. Review.
New risk factors for atherosclerosis and patient risk assessment.
Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. Fruchart JC, et al. Among authors: duriez p. Circulation. 2004 Jun 15;109(23 Suppl 1):III15-9. doi: 10.1161/01.CIR.0000131513.33892.5b. Circulation. 2004. PMID: 15198961 Review.
Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression.
Tailleux A, Gozzo A, Torpier G, Martin-Nizard F, Bonnefont-Rousselot D, Lemdani M, Furman C, Foricher R, Chevé G, Yous S, Micard F, Bordet R, Gardes-Albert M, Lesieur D, Teissier E, Fruchart JC, Fiévet C, Duriez P. Tailleux A, et al. Among authors: duriez p. J Cardiovasc Pharmacol. 2005 Sep;46(3):241-9. doi: 10.1097/01.fjc.0000175232.11079.7e. J Cardiovasc Pharmacol. 2005. PMID: 16116326
Peroxisome proliferator activated receptors and stroke.
Fruchart JC, Bordet R, Duriez P. Fruchart JC, et al. Among authors: duriez p. Curr Atheroscler Rep. 2003 Sep;5(5):331-2. doi: 10.1007/s11883-003-0001-6. Curr Atheroscler Rep. 2003. PMID: 12911841 No abstract available.
Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta.
Tailleux A, Torpier G, Bonnefont-Rousselot D, Lestavel S, Lemdani M, Caudeville B, Furman C, Foricher R, Gardes-Albert M, Lesieur D, Rolando C, Teissier E, Fruchart JC, Clavey V, Fievet C, Duriez P. Tailleux A, et al. Among authors: duriez p. Biochem Biophys Res Commun. 2002 May 10;293(3):1114-23. doi: 10.1016/S0006-291X(02)00336-4. Biochem Biophys Res Commun. 2002. PMID: 12051775
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
Tailleux A, Duriez P, Fruchart JC, Clavey V. Tailleux A, et al. Among authors: duriez p. Atherosclerosis. 2002 Sep;164(1):1-13. doi: 10.1016/s0021-9150(01)00751-1. Atherosclerosis. 2002. PMID: 12119188 Review.
238 results